Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.2K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

2.0K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
2.0K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.2K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.3K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.4K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical validation of respiratory outcomes for a patch-based polysomnography system.

ERJ open research·2026
Same author

[Safety of diagnostic flexible bronchoscopy in adults S2k-Guideline of the German Respiratory Society].

Pneumologie (Stuttgart, Germany)·2026
Same author

[Mechanisms of dyspnea].

Pneumologie (Stuttgart, Germany)·2026
Same author

Reply on behalf of the European Respiratory Society and European Sleep Research Society task force.

The European respiratory journal·2026
Same author

Sleep without borders starts here: Principles and pathways for sleep health promotion.

Sleep medicine: X·2026
Same author

Sex-Specific Phenotypes and Outcomes in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease: Results from the INSIGHTS-ILD Registry.

Respiration; international review of thoracic diseases·2026

Related Experiment Video

Updated: Apr 15, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K

Smoking-related interstitial lung disease.

Lars Hagmeyer1, Winfried Randerath

  • 1Bethanien Hospital Solingen.

Deutsches Arzteblatt International
|March 24, 2015
PubMed
Summary

Smoking-related interstitial lung diseases (SR-ILDs) require consideration in smokers with cough or dyspnea. Early diagnosis and smoking cessation improve outcomes for these heterogeneous lung conditions.

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Toxicology

Background:

  • Smoking-related interstitial lung diseases (SR-ILDs) represent a diverse group of conditions with significant clinical impact.
  • Epidemiological data for SR-ILDs remain limited, underscoring the need for further research.

Purpose of the Study:

  • To review current knowledge on the pathophysiology and treatment of SR-ILDs.
  • To highlight diagnostic approaches and therapeutic strategies for improving patient outcomes.

Main Methods:

  • A selective literature search was conducted in PubMed to identify pertinent studies.
  • Review of available data on the epidemiology, diagnosis, and treatment of various SR-ILDs.

Main Results:

More Related Videos

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
06:12

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

1.4K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

8.0K

Related Experiment Videos

Last Updated: Apr 15, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K
Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
06:12

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

1.4K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

8.0K
  • High-resolution computed tomography (HRCT) is crucial for differential diagnosis, often obviating the need for lung biopsy.
  • Oncogenic mutations are implicated in pulmonary Langerhans-cell histiocytosis (PLCH); cladribine and vemurafenib show future therapeutic potential.
  • Desquamative interstitial pneumonia (DIP) and respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) require careful differentiation, with steroids used for DIP.
  • Antifibrotic agents like pirfenidone and nintedanib can slow disease progression in idiopathic pulmonary fibrosis (IPF).
  • Smoking is a risk factor for multiple conditions including CPFE, RA-ILD, PAP, AEP, and DAH.

    • Conclusions:

    • SR-ILDs should be considered in smokers presenting with exertional dyspnea or nonproductive cough.
    • Referral to a pulmonary specialist is recommended for suspected SR-ILD cases.
    • Prompt treatment and smoking cessation are vital for enhancing clinical outcomes, especially in acute and progressive forms of SR-ILD.